NYSE:CRL - Charles River Laboratories International Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $325.43
Forecasted Upside: -11.27 %
Number of Analysts: 14
Breakdown:
0 Sell Ratings
4 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$366.78 As of 06/24/2021 01:00 AM ET

▼ -0.17 (-0.05%)

1 month | 3 months | 12 months

Get New Charles River Laboratories International Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CRL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRL

^$325.43

▼ -11.27% Downside Potential

This price target is based on 14 analysts offering 12 month price targets for Charles River Laboratories International in the last 3 months. The average price target is $325.43, with a high forecast of $400.00 and a low forecast of $192.00. The average price target represents a -11.27% upside from the last price of $366.78.

Current Consensus is Buy

The current consensus among 14 investment analysts is to buy stock in Charles River Laboratories International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/31/2019

1 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/30/2020

1 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/28/2020

1 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/26/2020

1 strong buy ratings
13 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/25/2020

0 strong buy ratings
11 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/25/2021

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/31/2021	Robert W. Baird	Reiterated Rating	Buy		Medium
5/28/2021	Credit Suisse Group	Boost Price Target	Neutral	$342.00 ➝ $352.00	Low
5/28/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target	Neutral	$350.00 ➝ $355.00	Low
5/28/2021	JPMorgan Chase & Co.	Boost Price Target	Positive ➝ Overweight	$375.00 ➝ $390.00	Medium
5/28/2021	Citigroup	Boost Price Target	Neutral	$350.00 ➝ $355.00	Medium
5/25/2021	Truist Securities	Boost Price Target	Buy	$324.00 ➝ $369.00	Medium
5/14/2021	KeyCorp	Boost Price Target	Overweight	$340.00 ➝ $360.00	High
5/5/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$334.00 ➝ $354.00	Medium
5/5/2021	Robert W. Baird	Boost Price Target	Outperform	$338.00 ➝ $400.00	Medium
2/25/2021	Morgan Stanley	Boost Price Target	Overweight	$280.00 ➝ $350.00	Medium
2/18/2021	Truist	Boost Price Target		$256.00 ➝ $324.00	Medium
2/18/2021	Credit Suisse Group	Boost Price Target	Neutral	$259.00 ➝ $301.00	High
2/18/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$250.00 ➝ $334.00	High
12/22/2020	Argus	Boost Price Target	Buy	$235.00 ➝ $265.00	Low
12/16/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Low
12/16/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$270.00 ➝ $250.00	N/A
11/24/2020	KeyCorp	Boost Price Target	Overweight	$233.00 ➝ $256.00	High
11/3/2020	Truist	Boost Price Target		$237.00 ➝ $256.00	Low
10/30/2020	Morgan Stanley	Boost Price Target	Overweight	$245.00 ➝ $260.00	Medium
10/30/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$235.00 ➝ $250.00	Medium
9/14/2020	Argus	Boost Price Target	Buy	$190.00 ➝ $235.00	Low
9/10/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$213.00 ➝ $254.00	High
8/18/2020	KeyCorp	Boost Price Target	Overweight	$186.00 ➝ $233.00	Low
8/6/2020	Morgan Stanley	Boost Price Target	Overweight	$175.00 ➝ $245.00	Low
8/6/2020	Citigroup	Boost Price Target	Buy	$190.00 ➝ $255.00	Low
7/21/2020	UBS Group	Boost Price Target	Buy	$200.00 ➝ $236.00	Low
7/1/2020	Bank of America	Upgrade	Neutral ➝ Buy	$192.00	Low
5/26/2020	Argus	Boost Price Target	Average ➝ Buy	$150.00 ➝ $190.00	Medium
5/13/2020	UBS Group	Upgrade	Neutral ➝ Buy	$177.00 ➝ $200.00	Low
5/12/2020	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$190.00 ➝ $174.00	Medium
5/8/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$160.00 ➝ $180.00	Low
5/8/2020	Robert W. Baird	Boost Price Target	Outperform	$156.00 ➝ $175.00	Low
5/8/2020	Credit Suisse Group	Lower Price Target	Neutral	$162.00 ➝ $159.00	Low
5/8/2020	Morgan Stanley	Boost Price Target	Overweight	$152.00 ➝ $175.00	Medium
5/8/2020	Citigroup	Boost Price Target	Buy	$165.00 ➝ $190.00	Medium
5/8/2020	SunTrust Banks	Boost Price Target	Buy	$130.00 ➝ $194.00	Medium
4/21/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$139.00	High
4/9/2020	Citigroup	Lower Price Target	Buy	$200.00 ➝ $165.00	Medium
4/6/2020	SunTrust Banks	Boost Price Target	Buy	$124.00 ➝ $130.00	High
3/30/2020	Wells Fargo & Company	Lower Price Target	Overweight	$200.00 ➝ $145.00	High
3/27/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$152.00	High
3/26/2020	Barclays	Lower Price Target	Equal Weight	$170.00 ➝ $154.00	High
3/23/2020	Jefferies Financial Group	Lower Price Target	Buy	$200.00 ➝ $139.00	Medium
3/17/2020	SunTrust Banks	Lower Price Target	Buy	$188.00 ➝ $124.00	High
3/2/2020	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$190.00	High
2/18/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$169.00 ➝ $203.00	Low
2/12/2020	Morgan Stanley	Boost Price Target	Equal Weight	$156.00 ➝ $176.00	Medium
2/12/2020	Robert W. Baird	Reiterated Rating	Outperform	$165.00 ➝ $185.00	Medium
2/12/2020	Barclays	Reiterated Rating	Hold	$170.00	Low
2/12/2020	Citigroup	Boost Price Target	Buy	$185.00 ➝ $200.00	Low
2/11/2020	Cfra	Boost Price Target	Strong-Buy	$165.00 ➝ $180.00	Medium
1/10/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$143.00 ➝ $179.00	Low
1/7/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$180.00	Low
1/6/2020	Citigroup	Initiated Coverage	Buy	$185.00	Low
12/17/2019	Robert W. Baird	Boost Price Target	Outperform	$160.00 ➝ $165.00	Medium
12/9/2019	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$151.00 ➝ $162.00	Medium
11/19/2019	Argus	Reiterated Rating	Buy	$170.00	Low
10/18/2019	Bank of America	Downgrade	Buy ➝ Neutral	$150.00	High
9/16/2019	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$156.00 ➝ $162.00	Medium
9/13/2019	Credit Suisse Group	Set Price Target	Hold	$138.00	Medium
6/10/2019	SVB Leerink	Initiated Coverage	Outperform	$155.00	Low
4/30/2019	Evercore ISI	Reiterated Rating	Outperform ➝ Outperform	$160.00	Low
4/2/2019	Wolfe Research	Initiated Coverage	Market Perform		Medium
3/18/2019	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$135.00 ➝ $145.00	Medium
3/11/2019	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$140.00 ➝ $151.00	Low
2/14/2019	Barclays	Reiterated Rating	Hold	$135.00	Low
2/14/2019	SunTrust Banks	Boost Price Target	Positive ➝ Buy	$151.00	Low
2/14/2019	Jefferies Financial Group	Reiterated Rating	Buy	$162.00	Low
12/14/2018	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy		Low
12/4/2018	Raymond James	Reiterated Rating	Buy	$150.00	Low
12/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$112.00 ➝ $136.00	Low
11/8/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$144.00 ➝ $148.00	Medium
11/8/2018	Raymond James	Boost Price Target	Outperform ➝ Buy	$140.00 ➝ $150.00	Medium
11/7/2018	Royal Bank of Canada	Set Price Target	Outperform ➝ Buy	$131.00 ➝ $147.00	N/A
10/9/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$140.00	Low
9/25/2018	Credit Suisse Group	Boost Price Target	Neutral ➝ Neutral	$121.00 ➝ $128.00	High
9/17/2018	Robert W. Baird	Boost Price Target	Outperform	$133.00 ➝ $141.00	Low
9/11/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Hold	$102.00 ➝ $112.00	Low
8/27/2018	Argus	Boost Price Target	Buy ➝ Buy	$125.00 ➝ $140.00	Low
8/23/2018	Raymond James	Upgrade	Market Perform ➝ Outperform	$140.00	Medium
8/21/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Neutral	$129.00 ➝ $121.00	Low
8/9/2018	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $120.00	Medium
8/9/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$140.00 ➝ $145.00	High
8/9/2018	SunTrust Banks	Boost Price Target	Buy	$135.00	Medium
7/20/2018	Jefferies Financial Group	Reiterated Rating	Buy	$140.00	Low
7/17/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$131.00	High
7/16/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$120.00 ➝ $125.00	Low
6/15/2018	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$115.85 ➝ $130.00	High
4/20/2018	Mitsubishi UFJ Financial Group	Initiated Coverage	Neutral	$115.00	Low
3/14/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$94.00 ➝ $102.00	Low
2/16/2018	Barclays	Reiterated Rating	Hold	$110.00	Low
2/15/2018	Credit Suisse Group	Reiterated Rating	Hold	$108.00	Low
2/14/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$110.00 ➝ $120.00	Medium
2/14/2018	SunTrust Banks	Upgrade	Hold ➝ Buy	$107.66 ➝ $125.00	Medium
2/13/2018	Royal Bank of Canada	Set Price Target	Hold	$116.00	High
2/13/2018	Robert W. Baird	Set Price Target	Buy	$123.00	High
1/22/2018	SunTrust Banks	Downgrade	Buy ➝ Hold	$107.89 ➝ $111.00	Medium
1/18/2018	Evercore ISI	Initiated Coverage	In ➝ In-Line	$117.00	Low
12/13/2017	Argus	Initiated Coverage	Buy ➝ Buy	$120.00	Medium
11/17/2017	SunTrust Banks	Reiterated Rating	Buy	$113.00	N/A
11/13/2017	Robert W. Baird	Set Price Target	Buy	$117.00	N/A
11/10/2017	Bank of America	Lower Price Target	Buy	$117.00 ➝ $115.00	N/A
10/16/2017	Credit Suisse Group	Reiterated Rating	Neutral	$95.00 ➝ $112.00	N/A
10/9/2017	Jefferies Financial Group	Boost Price Target	Buy	$120.00 ➝ $130.00	N/A
9/19/2017	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform	$110.00	Medium
9/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$120.00	Low
9/1/2017	Robert W. Baird	Reiterated Rating	Buy	$114.00	Low
7/19/2017	Barclays	Reiterated Rating	Hold	$102.00	Low
6/30/2017	Jefferies Financial Group	Reiterated Rating	Buy	$121.00	Low
6/28/2017	Citigroup	Reiterated Rating	Neutral	$91.00 ➝ $104.00	Low
6/14/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low
6/6/2017	Credit Suisse Group	Reiterated Rating	Neutral	$89.00 ➝ $95.00	Low
5/13/2017	Barclays	Set Price Target	Hold	$90.00	Low
5/11/2017	Citigroup	Reiterated Rating	Neutral	$90.00 ➝ $104.00	Low
4/21/2017	Jefferies Financial Group	Reiterated Rating	Buy	$106.00	Low
3/16/2017	Jefferies Financial Group	Reiterated Rating	Buy		High
2/15/2017	UBS Group	Boost Price Target		$84.00	N/A
2/15/2017	Jefferies Financial Group	Boost Price Target	Buy	$104.00	N/A
1/4/2017	Evercore ISI	Upgrade	Hold ➝ Buy	$86.50	N/A
12/20/2016	Jefferies Financial Group	Reiterated Rating	Buy	$93.00	N/A
12/16/2016	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$75.00 ➝ $77.00	N/A
11/30/2016	Barclays	Upgrade	Underweight ➝ Equal Weight	$65.00 ➝ $77.00	N/A
11/18/2016	Bank of America	Set Price Target	Buy	$93.00	N/A
9/30/2016	Credit Suisse Group	Reiterated Rating	Hold ➝ Neutral		N/A
9/6/2016	UBS Group	Downgrade	Neutral ➝ Sell	$83.00 ➝ $78.00	N/A
8/4/2016	Evercore ISI	Reiterated Rating	Hold	$83.50 ➝ $91.50	N/A
8/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$94.00 ➝ $100.00	N/A
8/4/2016	Citigroup	Boost Price Target	Neutral	$85.00 ➝ $90.00	N/A

(Data available from 6/24/2016 forward)

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.

Today's Range

Now: $366.78

$366.22

$370.58

50 Day Range

MA: $336.12

$316.76

$366.95

52 Week Range

Now: $366.78

$167.55

$370.58

Volume

306,112 shs

Average Volume

483,729 shs

Market Capitalization

$18.43 billion

P/E Ratio

49.70

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

The following sell-side analysts have issued research reports on Charles River Laboratories International in the last year: Argus, Bank of America Co., Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Robert W. Baird, Smith Barney Citigroup, Truist, Truist Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for CRL.

What is the current price target for Charles River Laboratories International?

14 Wall Street analysts have set twelve-month price targets for Charles River Laboratories International in the last year. Their average twelve-month price target is $325.43, suggesting a possible downside of 11.3%. Robert W. Baird has the highest price target set, predicting CRL will reach $400.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $192.00 for Charles River Laboratories International in the next year.
View the latest price targets for CRL.

What is the current consensus analyst rating for Charles River Laboratories International?

Charles River Laboratories International currently has 4 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRL will outperform the market and that investors should add to their positions of Charles River Laboratories International.
View the latest ratings for CRL.

What other companies compete with Charles River Laboratories International?

Other companies that are similar to Charles River Laboratories International include Thermo Fisher Scientific, Illumina, Agilent Technologies, Mettler-Toledo International, Waters, Bio-Rad Laboratories, PerkinElmer, Bio-Techne, Bruker, Pacific Biosciences of California, Luminex, Fluidigm, Harvard Bioscience, aTyr Pharma and BG Medicine.

How do I contact Charles River Laboratories International's investor relations team?

Charles River Laboratories International's physical mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company's listed phone number is 781-222-6000 and its investor relations email address is [email protected] The official website for Charles River Laboratories International is www.criver.com.